Passa al contenuto
Merck
Tutte le immagini(3)

Documenti

C6427

Sigma-Aldrich

Clindamycin 2-phosphate

aminoglycoside antibiotic

Sinonimo/i:

Clindamycin 2-dihydrogen phosphate

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C18H34ClN2O8PS
Numero CAS:
Peso molecolare:
504.96
Numero CE:
Numero MDL:
Codice UNSPSC:
51102829
ID PubChem:
NACRES:
NA.76

Forma fisica

solid

Solubilità

DMSO: 224 mg/mL at 25 °C

Spettro attività antibiotica

Gram-positive bacteria

Modalità d’azione

protein synthesis | interferes

Temperatura di conservazione

2-8°C

Stringa SMILE

CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC([C@H](C)Cl)C2O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]2O

InChI

1S/C18H34ClN2O8PS/c1-5-6-10-7-11(21(3)8-10)17(24)20-12(9(2)19)15-13(22)14(23)16(18(28-15)31-4)29-30(25,26)27/h9-16,18,22-23H,5-8H2,1-4H3,(H,20,24)(H2,25,26,27)/t9-,10+,11-,12?,13+,14-,15?,16+,18+/m0/s1
UFUVLHLTWXBHGZ-MWBQRTRKSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

Chemical structure: macrolide

Applicazioni

Clindamycin 2-phosphate is an aminoglycoside antibiotic that has been used to study the cytoxicity of antibiotics on human cell lines , Bacterial protein synthesis and peptide translation, and the inhibition of human Tyrosyl-DNA Phosphodiesterase .

Azioni biochim/fisiol

Clindamycin 2-phosphate is a pharmacological tyrosyl-DNA phosphodiesterase (Tdp1) inhibitor. Clindamycin 2-phosphate can repair DNA topoisomerase I-DNA covalent complexes by hydrolyzing the tyrosyl-DNA bond. It inhibits protein synthesis in bacteria by binding the 50s ribosomal subunit. . Spectrum of Activity: Gram positive cocci and taxoplasma. Especially active against anaerobic bacteria.
Spectrum of Activity: Gram positive cocci and taxoplasma. Especially active against anaerobic bacteria.
Mode of Action: Inhibits protein synthesis in bacterial by binding the 50s ribosomal subunit.

Altre note

Antibacterial and antiprotozoal antibiotic of the licosamide class.
Keep container tightly closed in a dry and well-ventilated place.

Pittogrammi

Exclamation mark

Avvertenze

Warning

Indicazioni di pericolo

Classi di pericolo

Acute Tox. 4 Oral - Eye Irrit. 2 - Lact. - Skin Sens. 1

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Dispositivi di protezione individuale

dust mask type N95 (US), Eyeshields, Gloves


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Zhiyong Liao et al.
Molecular pharmacology, 70(1), 366-372 (2006-04-19)
DNA topoisomerase I (Top1) is the target of camptothecin, and novel Top1 inhibitors are in development as anticancer agents. Top1 inhibitors damage DNA by trapping covalent complexes between the Top1 catalytic tyrosine and the 3'-end of the broken DNA. Tyrosyl-DNA
M Badawy Abdel-Naser et al.
Expert opinion on pharmacotherapy, 9(16), 2931-2937 (2008-10-22)
Clindamycin phosphate 1.2% together with tretinoin 0.025% as a gel (CTG) is a topical formulation of a fixed and stable combination approved by the FDA for the treatment of acne vulgaris in patients 12 years of age or older. The
Diane Thiboutot et al.
Journal of the American Academy of Dermatology, 59(5), 792-800 (2008-09-23)
We sought to evaluate efficacy, safety, and tolerability of a combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (clindamycin-BPO 2.5%) aqueous gel in moderate to severe acne vulgaris. A total of 2813 patients, aged 12 years or older, were
Lawrence F Eichenfield et al.
Pediatric dermatology, 26(3), 257-261 (2009-08-27)
Treatments for mild to moderately severe acne usually combine retinoid and antimicrobial therapy. Recently, the US FDA approved the combination of 1.2% clindamycin (CLIN) and 0.025% tretinoin (RA) in a novel gel formulation for the treatment of mild to moderate
C Hascicek et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 77(1), 116-121 (2010-11-23)
The aim of this work was to study the clindamycin release kinetics from floating delivery systems consisting of two modules assembled in void configuration, according to the modified release technology platform known as Dome Matrix®. Two modules differently shaped, i.e.

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.